Zacks Research Issues Pessimistic Estimate for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Zacks Research dropped their FY2024 earnings per share estimates for shares of Axsome Therapeutics in a note issued to investors on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($5.42) per share for the year, down from their prior estimate of ($5.32). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($1.71) EPS, Q2 2025 earnings at ($1.60) EPS, Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.77) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.67) EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Axsome Therapeutics in a report on Tuesday, December 31st. Mizuho decreased their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, December 31st. Needham & Company LLC reissued a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research note on Monday. Robert W. Baird raised their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $127.29.

Axsome Therapeutics Trading Down 1.4 %

Shares of Axsome Therapeutics stock opened at $82.57 on Thursday. The company has a 50 day simple moving average of $92.48 and a two-hundred day simple moving average of $89.04. The firm has a market cap of $4.00 billion, a PE ratio of -12.64 and a beta of 1.04. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $105.00. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same period last year, the business earned ($1.32) earnings per share.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its holdings in Axsome Therapeutics by 5.1% in the second quarter. Rhumbline Advisers now owns 54,931 shares of the company’s stock valued at $4,422,000 after acquiring an additional 2,674 shares during the period. Arizona State Retirement System boosted its holdings in shares of Axsome Therapeutics by 2.1% in the second quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock worth $695,000 after buying an additional 177 shares during the last quarter. WINTON GROUP Ltd grew its position in Axsome Therapeutics by 156.6% during the second quarter. WINTON GROUP Ltd now owns 8,823 shares of the company’s stock valued at $710,000 after buying an additional 5,385 shares during the period. Sofinnova Investments Inc. purchased a new stake in Axsome Therapeutics during the second quarter valued at approximately $24,971,000. Finally, XTX Topco Ltd increased its holdings in Axsome Therapeutics by 177.9% during the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock valued at $902,000 after buying an additional 7,173 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.